INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Hackensack University Medical Center
Hackensack, Estados UnidosPublicaciones en colaboración con investigadores/as de Hackensack University Medical Center (9)
2019
-
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
The Lancet, Vol. 393, Núm. 10168, pp. 229-240
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2014
-
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477
-
The IASLC/ITMIG thymic epithelial tumors staging project: Proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors
Journal of Thoracic Oncology, Vol. 9, Núm. 9, pp. S65-S72
-
The IASLC/ITMIG thymic epithelial tumors staging project: Proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors
Journal of Thoracic Oncology, Vol. 9, Núm. 9, pp. S81-S87
-
The IASLC/ITMIG thymic epithelial tumors staging project: Proposals for the T component for the forthcoming (8th) edition of the TNM classification of malignant tumors
Journal of Thoracic Oncology, Vol. 9, Núm. 9, pp. S73-S80
2013
-
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma
Journal of Clinical Oncology
2012
-
Management of treatment-emergent peripheral neuropathy in multiple myeloma
Leukemia, Vol. 26, Núm. 4, pp. 595-608
2009
-
Panobinostat and Bortezomib Phase I Trial in Multiple Myeloma
CLINICAL LYMPHOMA & MYELOMA